US announces trial payment program for care providers of dementia
patients
Send a link to a friend
[August 01, 2023]
(Reuters) - The U.S. government said on Monday it would trial a
new payment program for people who provide dementia care coordination
services for patients covered by the Medicare health plan.
The program includes services such as personalized assessments, care
plans for patients as well as 24/7 access to a support line. Medicare
said the program aims to delay long-term nursing home care.
The Medicare agency's pilot program will test a per-patient per-month
amount payment model for people who provide support services to patients
with dementia.
The model includes a care coordinator to help increase access to
clinical care as well as non-clinical services such as meals and
transportation through community-based organizations.
The program is for people suffering from dementia due to Alzheimer's
disease or other causes including vascular dementia, dementia with Lewy
bodies or abnormal deposits of protein inside nerve cells, among others.
[to top of second column]
|
Dr. Seth Gale points out evidence of
Alzheimer’s disease on PET scans at the Center for Alzheimer
Research and Treatment (CART) at Brigham And Women’s Hospital in
Boston, Massachusetts, U.S., March 30, 2023. REUTERS/Brian
Snyder/File Photo
The federal agency said it will open
applications for organizations interested in participating in the
program in autumn of this year. The trial is expected to run for
eight years beginning July 2024.
About 6.5 million Americans currently live with
Alzheimer's disease or another form of dementia, a number that is
projected to grow by nearly 14 million by 2060, according to
government data.
The new plan comes weeks after the U.S. Food and Drug Administration
approved Biogen and Eisai's Alzheimer's treatment Leqembi and
Medicare said it would begin paying for it widely.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra
Eluri)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |